Efficacy comparison on treating advanced non-small-cell lung cancer between using weekly docetaxel and using docetaxel associated with nedaplatin / 肿瘤研究与临床

Objective To compare the efficacy,toxicity and prognosis on treating advanced non-small-cell lung cancer (NSCLC) between using weekly docetaxel (DOC) and using DOC associated with nedaplatin(NDP).Methods 56 cases of NSCLC patients were retrospectively analyzed.Group A included 34 cases who were treated with weekly DOC (35 mg/m2,dl,8).Group B included 22 cases who were treated with DOC associated with NDP (DOC 35 mg/m2,dl,8,NDP 80 mg/m2,d2).One treatment cycle was 21 days.Efficacy,toxicity and prognosis were evaluated after 2 treatment cycles.Results RR of group A was 8.8 ％ (3/34).RR of group B was 27.3 ％ (6/22).DCR of group A was 50.0 ％ (17/34).DCR of group B was 63.6 ％ (14/22).PFS of group A was 2.3 months.PFS of group B was 5.1 months.OS of group A was 8.7 months.OS of group B was 10.5 months.1-year survival rate of group A was 26.5 ％.1-year survival rate of group B was 31.8 ％.The above comparisons were not statistically different (all P ＞ 0.05).In adverse reactions,hematologic toxicity in group B was greater than that in group A (x2 =4.877,P =0.027).Other adverse reactions such as gastrointestinal reactions,fatigue and so on were grade Ⅰ-Ⅱ.Conclusions The treatment of weekly DOC used in advanced NSCLC is safe,effective an low toxicity.There are no significant difference of RR and PFS between single DOC and DOC associated with NDP.

Advance on molecular markers of non-small-cell lung cancer / 肿瘤研究与临床

Clinical studies on non-small-cell lung cancer molecular markers have advanced lots of progress, which are benifited from the tumor molecular biology technology of development.The nearest studies and advances of non-small-cell lung cancer molecular markers are included in this paper.